Related Experiment Video

Updated: May 11, 2026

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study
03:05

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Published on: November 21, 2025

Efficacy and Safety of Ongericimab in Chinese Patients with Hypercholesterolemia: A Meta-analysis of Randomized

Muhammad Imaz Bhatti1, Muhammad Safiullah2, Maria Qadri3

  • 1Department of Medicine, King Edward Medical University, Lahore, 54000, Pakistan. imazbhatti4@gmail.com.

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|May 9, 2026
PubMed
Abstract

Insights

Ongericimab effectively lowers LDL-C and atherogenic lipoproteins in Chinese patients with hypercholesterolemia. This novel PCSK9 inhibitor demonstrates a safety profile similar to placebo, supporting its use as an adjunct therapy.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Genetics

Background:

  • Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a key lipid-lowering strategy.
  • Ongericimab is a new monoclonal antibody targeting PCSK9.
  • Hypercholesterolemia management often requires therapies beyond statins.

Purpose of the Study:

  • To evaluate the efficacy and safety of ongericimab in Chinese patients with hypercholesterolemia.
  • To assess the lipid-lowering effects of ongericimab.
  • To compare ongericimab's effectiveness against placebo.

Main Methods:

  • A meta-analysis of five randomized controlled trials (RCTs) involving 1415 patients.
  • Literature search across PubMed, Embase, Scopus, and ClinicalTrials.gov.
  • Random-effects model used for calculating effect estimates and 95% confidence intervals (CIs).

Main Results:

  • Ongericimab significantly reduced LDL-C (71%), Lp(a) (48%), ApoB (60%), total cholesterol (47%), and non-HDL-C (65%).
  • Dose-dependent effects observed for LDL-C, ApoB, TC, and non-HDL-C; Lp(a) reduction was consistent.
  • At 150 mg, ongericimab increased HDL-C (10%), ApoA1 (8%), and reduced triglycerides (23%).

Conclusions:

  • Ongericimab effectively reduces LDL-C and atherogenic lipoproteins in Chinese patients.
  • The drug exhibits a tolerability profile comparable to placebo.
  • Ongericimab shows potential as an adjunctive therapy for statin-intolerant or resistant patients.

More Related Videos

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials08:36

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials

Published on: April 19, 2024

Related Concept Videos

Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...